Company: EVGN
Filing Date: 2025-09-30
Form Type: POS AM
Source: 0001178913-25-003429
Chunk: 8

Company: Evogene Ltd.
Filing Date: 2025-09-30
Form: POS AM
Chunk 8
---
 and |
| • | the market price of our ordinary shares may decline.                                              |

Investors may experience significant dilution as a result of this offering and future offerings. The exercise of the Series A warrants and Series B warrants and the issuance of up to 3,384,616 ordinary shares underlying those warrants could cause our existing shareholders to experience dilution. The Selling Shareholder identified herein may sell from time to time up to 3,384,616 ordinary shares, constituting the shares underlying the Series A warrants and Series B warrants, which constitute approximately 38.83% of our issued and outstanding ordinary shares as of the date of this prospectus. Such sales could cause the market price of our ordinary shares to decline. Purchasers of the ordinary shares, as well as our existing shareholders, will experience significant dilution if the Selling Shareholder identified herein sells shares at prices significantly below the price at which it invested. In addition, we may also offer additional ordinary shares in the future, which may result in additional significant dilution. Future issuances or sales, or the potential for future issuances or sales, of our ordinary shares may cause the trading price of our ordinary shares to decline and could impair our ability to raise capital through subsequent equity offerings. We have issued a significant number of ordinary shares and we may do so in the future. Shares to be issued in future equity offerings could cause the market price of our ordinary shares to decline and could have an adverse effect on our earnings per share if and when we become profitable. In addition, future sales of our ordinary shares or other securities in the public markets, or the perception that these sales may occur, could cause the market price of our ordinary shares to decline, and could materially impair our ability to raise capital through the sale of additional securities. The market price of our ordinary shares could decline due to sales, or the announcements of proposed sales, of a large number of ordinary shares in the market, including sales of ordinary shares by our large shareholders, or the perception that these sales could occur. These sales or the perception that these sales could occur could also depress the market price of our ordinary shares and impair our ability to raise capital through the sale of additional equity securities or make it more difficult or impossible for us to sell equity securities in the future at a time and price that we deem appropriate. We cannot predict the effect that future sales of ordinary shares or other equity-related securities would have on the market price of our ordinary shares. Our Articles authorize our Board of Directors to, among other things,